53179-13-8 | Pirfenidone

Packsize	Purity	Availability	Price	Discounted Price
100mg	98%	in stock	$6.00	$4.00
250mg	98%	in stock	$10.00	$7.00
1g	98%	in stock	$18.00	$13.00
5g	98%	in stock	$43.00	$30.00
10g	95%	in stock	$50.00	$35.00
25g	95%	in stock	$113.00	$80.00
100g	95%	in stock	$416.00	$292.00

Description

• Catalog Number: AB46889
• Chemical Name: Pirfenidone
• CAS Number: 53179-13-8
• Molecular Formula: C12H11NO
• Molecular Weight: 185.2218
• MDL Number: MFCD00866047
• SMILES: Cc1ccc(=O)n(c1)c1ccccc1
• NSC Number: 748456

Computed Properties

• Complexity: 285
• Covalently-Bonded Unit Count: 1
• Heavy Atom Count: 14
• Hydrogen Bond Acceptor Count: 1
• Rotatable Bond Count: 1
• XLogP3: 1.9

Literature

• Pirfenidone protects against paraquat-induced lung injury and fibrosis in mice by modulation of inflammation, oxidative stress, and gene expression.

  Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association 20180201

• The K-Ras effector p38γ MAPK confers intrinsic resistance to tyrosine kinase inhibitors by stimulating EGFR transcription and EGFR dephosphorylation.

  The Journal of biological chemistry 20170908

• Human precision-cut liver slices as a model to test antifibrotic drugs in the early onset of liver fibrosis.

  Toxicology in vitro : an international journal published in association with BIBRA 20160901

• Effect of pirfenidone on proliferation, TGF-β-induced myofibroblast differentiation and fibrogenic activity of primary human lung fibroblasts.

  European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences 20140716

• Targeting the myofibroblast genetic switch: inhibitors of myocardin-related transcription factor/serum response factor-regulated gene transcription prevent fibrosis in a murine model of skin injury.

  The Journal of pharmacology and experimental therapeutics 20140601

• A new hope for idiopathic pulmonary fibrosis.

  The New England journal of medicine 20140529

• A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis.

  The New England journal of medicine 20140529

• Precision-cut liver slices as a model for the early onset of liver fibrosis to test antifibrotic drugs.

  Toxicology and applied pharmacology 20140115

• Antifibrotic effect of atorvastatin on paraquat-induced pulmonary fibrosis: role of PPARγ receptors.

  European journal of pharmacology 20131115

• Chronic potentiation of cardiac L-type Ca(2+) channels by pirfenidone.

  Cardiovascular research 20121101

• Fluorofenidone attenuates bleomycin-induced pulmonary inflammation and fibrosis in mice via restoring caveolin 1 expression and inhibiting mitogen-activated protein kinase signaling pathway.

  Shock (Augusta, Ga.) 20121101

• Effects of an anti-transforming growth factor-β agent (pirfenidone) on strabismus surgery in rabbits.

  Current eye research 20120901

• The big clinical trials in idiopathic pulmonary fibrosis.

  Current opinion in pulmonary medicine 20120901

• Into the matrix: targeting fibroblasts in pulmonary fibrosis.

  Current opinion in pulmonary medicine 20120901

• Effect of pirfenidone on pulmonary fibrosis due to paraquat poisoning in rats.

  Clinical toxicology (Philadelphia, Pa.) 20120901

• Pirfenidone treatment in idiopathic pulmonary fibrosis: too much of a great expectation?

  The European respiratory journal 20120901

• Genotoxic evaluation of pirfenidone using erythrocyte rodent micronucleus assay.

  Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association 20120801

• 2012 update on diabetic kidney disease: the expanding spectrum, novel pathogenic insights and recent clinical trials.

  Minerva medica 20120801

• Inhibitory effects of pirfenidone on dendritic cells and lung allograft rejection.

  Transplantation 20120727

• Treating idiopathic pulmonary fibrosis: current opportunities and future challenges.

  The clinical respiratory journal 20120701

• Pirfenidone: significant treatment effects in idiopathic pulmonary fibrosis.

  The clinical respiratory journal 20120701

• Re: A controlled clinical trial with pirfenidone in the treatment of pathological skin scarring caused by burns in pediatric patients.

  Annals of plastic surgery 20120701

• Update in diffuse parenchymal lung disease 2011.

  American journal of respiratory and critical care medicine 20120701

• Clinical highlights from the 2011 ERS Congress in Amsterdam.

  The European respiratory journal 20120601

• Assessing the treatment effect from multiple trials in idiopathic pulmonary fibrosis.

  European respiratory review : an official journal of the European Respiratory Society 20120601

• Unravelling the progressive pathophysiology of idiopathic pulmonary fibrosis.

  European respiratory review : an official journal of the European Respiratory Society 20120601

• Changing the idiopathic pulmonary fibrosis treatment approach and improving patient outcomes.

  European respiratory review : an official journal of the European Respiratory Society 20120601

• Simultaneous determination of dextromethorphan and dextrophan in rat plasma by LC-MS/MS and its application to a pharmacokinetic study.

  Die Pharmazie 20120601

• Immunotherapy in miscellaneous medical disorders Graves ophthalmopathy, asthma, and regional painful syndrome.

  The Medical clinics of North America 20120501

• p38γ mitogen-activated protein kinase (MAPK) confers breast cancer hormone sensitivity by switching estrogen receptor (ER) signaling from classical to nonclassical pathway via stimulating ER phosphorylation and c-Jun transcription.

  The Journal of biological chemistry 20120427

• Pirfenidone suppresses keloid fibroblast-embedded collagen gel contraction.

  Archives of dermatological research 20120401

• Pirfenidone treatment of idiopathic pulmonary fibrosis.

  Therapeutic advances in respiratory disease 20120401

• Synthesis and structure-activity relationship of 5-substituent-2(1H)-pyridone derivatives as anti-fibrosis agents.

  Bioorganic & medicinal chemistry letters 20120315

• Pirfenidone restricts Th2 differentiation in vitro and limits Th2 response in experimental liver fibrosis.

  European journal of pharmacology 20120305

• Management of idiopathic pulmonary fibrosis.

  Clinics in chest medicine 20120301

• [Idiopathic pulmonary fibrosis: modern guideline-concordant diagnostics and innovative treatment].

  Deutsche medizinische Wochenschrift (1946) 20120301

• Drugs of the future for Peyronie's disease.

  Medical hypotheses 20120201

• Design, synthesis and antifibrotic activities of carbohydrate-modified 1-(substituted aryl)-5-trifluoromethyl-2(1H) pyridones.

  Molecules (Basel, Switzerland) 20120117

• A controlled clinical trial with pirfenidone in the treatment of pathological skin scarring caused by burns in pediatric patients.

  Annals of plastic surgery 20120101

• The antifibrotic agent pirfenidone inhibits angiotensin II-induced cardiac hypertrophy in mice.

  Hypertension research : official journal of the Japanese Society of Hypertension 20120101

• Lymphoid tissue damage in HIV-1 infection depletes naïve T cells and limits T cell reconstitution after antiretroviral therapy.

  PLoS pathogens 20120101

• [Chronic kidney disease, new therapeutic approaches].

  La Revue du praticien 20120101

• Smoking and idiopathic pulmonary fibrosis.

  Pulmonary medicine 20120101

• Active roles of tumor stroma in breast cancer metastasis.

  International journal of breast cancer 20120101

• Pirfenidone inhibits transforming growth factor-β1-induced fibrogenesis by blocking nuclear translocation of Smads in human retinal pigment epithelial cell line ARPE-19.

  Molecular vision 20120101

• Therapeutic potential of ginger against renal injury induced by carbon tetrachloride in rats.

  TheScientificWorldJournal 20120101

• Pirfenidone inhibits TGF-β1-induced over-expression of collagen type I and heat shock protein 47 in A549 cells.

  BMC pulmonary medicine 20120101

• Antioxidants in kidney diseases: the impact of bardoxolone methyl.

  International journal of nephrology 20120101

• Antifibrotic effects of pirfenidone in rat proximal tubular epithelial cells.

  Renal failure 20120101

• Current and novel drug therapies for idiopathic pulmonary fibrosis.

  Drug design, development and therapy 20120101

• Adverse events of pirfenidone for the treatment of pulmonary fibrosis: a meta-analysis of randomized controlled trials.

  PloS one 20120101

• Clinical, molecular, and cellular features of non-Puerto Rican Hermansky-Pudlak syndrome patients of Hispanic descent.

  The Journal of investigative dermatology 20111201

• [Innovative therapeutics for idiopathic pulmonary fibrosis].

  Presse medicale (Paris, France : 1983) 20111201

• Design, synthesis and biological activity of original pyrazolo-pyrido-diazepine, -pyrazine and -oxazine dione derivatives as novel dual Nox4/Nox1 inhibitors.

  Bioorganic & medicinal chemistry 20111201

• [Role of medical treatment for symptomatic leiomyoma management in premenopausal women].

  Journal de gynecologie, obstetrique et biologie de la reproduction 20111201

• [Treatment of pulmonary fibrosis. New substances and new interventions].

  Der Internist 20111201

• Fluorofenidone suppresses epithelial-mesenchymal transition and the expression of connective tissue growth factor via inhibiting TGF-beta/Smads signaling in human proximal tubular epithelial cells.

  Die Pharmazie 20111201

• Pirfenidone: in idiopathic pulmonary fibrosis.

  Drugs 20110910

• Newer modes of treating interstitial lung disease.

  Current opinion in pulmonary medicine 20110901

• A first step against idiopathic pulmonary fibrosis.

  European respiratory review : an official journal of the European Respiratory Society 20110901

• Emerging potential treatments: new hope for idiopathic pulmonary fibrosis patients?

  European respiratory review : an official journal of the European Respiratory Society 20110901

• Fluorofenidone attenuates renal interstitial fibrosis in the rat model of obstructive nephropathy.

  Molecular and cellular biochemistry 20110801

• Pirfenidone in idiopathic pulmonary fibrosis: the CAPACITY program.

  Expert review of respiratory medicine 20110801

• Pirfenidone.

  Nature reviews. Drug discovery 20110701

• Pirfenidone for the treatment of Hermansky-Pudlak syndrome pulmonary fibrosis.

  Molecular genetics and metabolism 20110601

• Pirfenidone for diabetic nephropathy.

  Journal of the American Society of Nephrology : JASN 20110601

• [Interstitial lung disease].

  Deutsche medizinische Wochenschrift (1946) 20110601

• Trials and tribulations of new agents, novel biomarkers, and retarding renal progression.

  Journal of the American Society of Nephrology : JASN 20110601

• Antifibrotic activities of pirfenidone in animal models.

  European respiratory review : an official journal of the European Respiratory Society 20110601

• Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials.

  Lancet (London, England) 20110521

• Pirfenidone for idiopathic pulmonary fibrosis.

  Lancet (London, England) 20110521

• Evaluation of pirfenidone as a new postoperative antiscarring agent in experimental glaucoma surgery.

  Investigative ophthalmology & visual science 20110516

• Novel therapeutic approaches for pulmonary fibrosis.

  British journal of pharmacology 20110501

• Update on potential medical treatments for encapsulating peritoneal sclerosis; human and experimental data.

  International urology and nephrology 20110301

• [The study of effects of pirfenidone on the pulmonary fibrosis induced by paraquat in mice].

  Zhonghua lao dong wei sheng zhi ye bing za zhi = Zhonghua laodong weisheng zhiyebing zazhi = Chinese journal of industrial hygiene and occupational diseases 20110201

• Scarred by disease.

  Nature medicine 20110101

• Pirfenidone treatment of idiopathic pulmonary fibrosis.

  Therapeutics and clinical risk management 20110101

• A massive abdominal wall desmoid tumor occurring in a laparotomy scar: a case report.

  World journal of surgical oncology 20110101

• A Regenerative Antioxidant Protocol of Vitamin E and α-Lipoic Acid Ameliorates Cardiovascular and Metabolic Changes in Fructose-Fed Rats.

  Evidence-based complementary and alternative medicine : eCAM 20110101

• The protective effect of Malva sylvestris on rat kidney damaged by vanadium.

  Lipids in health and disease 20110101

• A rare cause of interstitial lung disease: Hermansky-Pudlak syndrome.

  Tuberkuloz ve toraks 20110101

• Membrane sealant Poloxamer P188 protects against isoproterenol induced cardiomyopathy in dystrophin deficient mice.

  BMC cardiovascular disorders 20110101

• Diffuse alveolar damage: a common phenomenon in progressive interstitial lung disorders.

  Pulmonary medicine 20110101

• Postoperative Acute Exacerbation of IPF after Lung Resection for Primary Lung Cancer.

  Pulmonary medicine 20110101

• Antifibrotic treatment and other new strategies for improving renal outcomes.

  Contributions to nephrology 20110101

• Decorin and colchicine as potential treatments for post-haemorrhagic ventricular dilatation in a neonatal rat model.

  Neonatology 20110101

• The clinical significance of 5% change in vital capacity in patients with idiopathic pulmonary fibrosis: extended analysis of the pirfenidone trial.

  Respiratory research 20110101

• Role of TGF-β signaling in inherited and acquired myopathies.

  Skeletal muscle 20110101

• Pharmacokinetics of pirfenidone after topical administration in rabbit eye.

  Molecular vision 20110101

• An alternative therapy for idiopathic pulmonary fibrosis by doxycycline through matrix metalloproteinase inhibition.

  Lung India : official organ of Indian Chest Society 20110101

• Stem cell therapy for idiopathic pulmonary fibrosis: a protocol proposal.

  Journal of translational medicine 20110101

• Exploratory analysis of a phase III trial of pirfenidone identifies a subpopulation of patients with idiopathic pulmonary fibrosis as benefiting from treatment.

  Respiratory research 20110101

• Treatment with etanercept in a patient with rheumatoid arthritis-associated interstitial lung disease.

  Clinical medicine insights. Case reports 20110101

• In vitro effects of pirfenidone on cardiac fibroblasts: proliferation, myofibroblast differentiation, migration and cytokine secretion.

  PloS one 20110101

• Safety of postoperative administration of human urinary trypsin inhibitor in lung cancer patients with idiopathic pulmonary fibrosis.

  PloS one 20110101

• [Idiopathic pulmonary fibrosis -- progress in sight].

  Duodecim; laaketieteellinen aikakauskirja 20110101

• The DOCA-Salt Hypertensive Rat as a Model of Cardiovascular Oxidative and Inflammatory Stress.

  Current cardiology reviews 20101101

• Pirfenidone mitigates left ventricular fibrosis and dysfunction after myocardial infarction and reduces arrhythmias.

  Heart rhythm 20101001

• [Pirfenidone diminishes SiO2 induced lung fibrosis in rats].

  Zhonghua lao dong wei sheng zhi ye bing za zhi = Zhonghua laodong weisheng zhiyebing zazhi = Chinese journal of industrial hygiene and occupational diseases 20101001

• Non-steroid agents for idiopathic pulmonary fibrosis.

  The Cochrane database of systematic reviews 20100908

• Oxidative stress and antioxidants in interstitial lung disease.

  Current opinion in pulmonary medicine 20100901

• Progress toward novel treatments for chronic kidney disease.

  Journal of renal nutrition : the official journal of the Council on Renal Nutrition of the National Kidney Foundation 20100901

• [Interstitial lung diseases - historical development, current status, future prospects].

  Pneumologie (Stuttgart, Germany) 20100901

• Pirfenidone in idiopathic pulmonary fibrosis.

  The European respiratory journal 20100901

• Staphylococcal enterotoxins.

  Toxins 20100801

• Current and future treatment options in idiopathic pulmonary fibrosis.

  Inflammation & allergy drug targets 20100701

• Regulatory watch: Surprise setback for lung fibrosis drug highlights trial challenges.

  Nature reviews. Drug discovery 20100701

• Pirfenidone in idiopathic pulmonary fibrosis.

  Drugs of today (Barcelona, Spain : 1998) 20100701

• Antifibrotic effect of Pirfenidone on orbital fibroblasts of patients with thyroid-associated ophthalmopathy by decreasing TIMP-1 and collagen levels.

  Investigative ophthalmology & visual science 20100601

• New pharmacological treatments for improving renal outcomes in diabetes.

  Nature reviews. Nephrology 20100601

• Investigational approaches to therapies for idiopathic pulmonary fibrosis.

  Expert opinion on investigational drugs 20100601

• Pirfenidone: antifibrotic agent for idiopathic pulmonary fibrosis.

  Expert review of respiratory medicine 20100601

• Molecular basis and current treatment for alcoholic liver disease.

  International journal of environmental research and public health 20100501

• Pirfenidone in idiopathic pulmonary fibrosis.

  The European respiratory journal 20100401

• Idiopathic pulmonary fibrosis and pirfenidone.

  The European respiratory journal 20100401

• FDA panel likes new treatment for idiopathic pulmonary fibrosis.

  Managed care (Langhorne, Pa.) 20100401

• Renoprotective properties of pirfenidone in subtotally nephrectomized rats.

  European journal of pharmacology 20100310

• Inhibition of matrix deposition: a new strategy for prevention of restenosis after balloon angioplasty.

  Journal of cardiovascular pharmacology 20100201

• Pirfenidone: an anti-fibrotic therapy for progressive kidney disease.

  Expert opinion on investigational drugs 20100201

• Systemic myostatin inhibition via liver-targeted gene transfer in normal and dystrophic mice.

  PloS one 20100101

• Association between transforming growth factor beta1 polymorphisms and atrial fibrillation in essential hypertensive subjects.

  Journal of biomedical science 20100101

• Respiratory symptoms and disease characteristics as predictors of pulmonary function abnormalities in patients with rheumatoid arthritis: an observational cohort study.

  Arthritis research & therapy 20100101

• Clinical use of biomarkers of survival in pulmonary fibrosis.

  Respiratory research 20100101

• Interstitial lung diseases in children.

  Orphanet journal of rare diseases 20100101

• Interstitial lung disease in connective tissue diseases: evolving concepts of pathogenesis and management.

  Arthritis research & therapy 20100101

• The multifaceted role of pirfenidone and its novel targets.

  Fibrogenesis & tissue repair 20100101

• Gateways to clinical trials.

  Methods and findings in experimental and clinical pharmacology 20100101

• Insulin resistance and glycemic abnormalities are associated with deterioration of left ventricular diastolic function: a cross-sectional study.

  Cardiovascular diabetology 20100101

• Experimental models of duchenne muscular dystrophy: relationship with cardiovascular disease.

  The open cardiovascular medicine journal 20100101

• Inflammatory cytokines and atrial fibrillation: current and prospective views.

  Journal of inflammation research 20100101

• Alveolar macrophage dysregulation in Hermansky-Pudlak syndrome type 1.

  American journal of respiratory and critical care medicine 20091201

• Fibrogenesis in kidney transplantation: potential targets for prevention and therapy.

  Transplantation 20091127

• Pirfenidone inhibits carbon tetrachloride- and albumin complex-induced liver fibrosis in rodents by preventing activation of hepatic stellate cells.

  Clinical and experimental pharmacology & physiology 20091001

• Pirfenidone: a potential therapeutic option in the treatment of liver fibrosis.

  Clinical and experimental pharmacology & physiology 20091001

• Fluorofenidone attenuates collagen I and transforming growth factor-beta1 expression through a nicotinamide adenine dinucleotide phosphate oxidase-dependent way in NRK-52E cells.

  Nephrology (Carlton, Vic.) 20090901

• Pirfenidone inhibits T-cell activation, proliferation, cytokine and chemokine production, and host alloresponses.

  Transplantation 20090815

• Effects of pirfenidone on proliferation, migration, and collagen contraction of human Tenon's fibroblasts in vitro.

  Investigative ophthalmology & visual science 20090801

• Effect of food and antacids on the pharmacokinetics of pirfenidone in older healthy adults.

  Pulmonary pharmacology & therapeutics 20090801

• Pirfenidone is renoprotective in diabetic kidney disease.

  Journal of the American Society of Nephrology : JASN 20090801

• Effects of intravenous administration of pirfenidone on horses with experimentally induced endotoxemia.

  American journal of veterinary research 20090801

• [Pharmacological properties and clinical effects of the antifibrotic agent pirfenidone (Pirespa) for treatment of idiopathic pulmonary fibrosis].

  Nihon yakurigaku zasshi. Folia pharmacologica Japonica 20090801

• Recent advances in pharmacotherapy of atrial fibrillation.

  Indian journal of pharmacology 20090801

• Recent advances in the treatment of systemic sclerosis.

  Clinical reviews in allergy & immunology 20090601

• Established and newly proposed mechanisms of chronic cyclosporine nephropathy.

  The Korean journal of internal medicine 20090601

• Advances in understanding of idiopathic pulmonary fibrosis.

  Chinese medical journal 20090405

• Permutation test following covariate-adaptive randomization in randomized controlled trials.

  Journal of biopharmaceutical statistics 20090101

• Macrophage derived chemokine (CCL22), thymus and activation-regulated chemokine (CCL17), and CCR4 in idiopathic pulmonary fibrosis.

  Respiratory research 20090101

• Liver fibrosis secondary to bile duct injury: correlation of Smad7 with TGF-beta and extracellular matrix proteins.

  BMC gastroenterology 20090101

• Late treatment with imatinib mesylate ameliorates radiation-induced lung fibrosis in a mouse model.

  Radiation oncology (London, England) 20090101

• New developments in the therapy of pulmonary fibrosis.

  Advances in pharmacology (San Diego, Calif.) 20090101

• The role of long-term doxycycline in patients of idiopathic pulmonaryfibrosis: The results of an open prospective trial.

  Lung India : official organ of Indian Chest Society 20090101

• Optimal treatment for idiopathic pulmonary fibrosis.

  Thorax 20081201

• Role of TGF-beta on cardiac structural and electrical remodeling.

  Vascular health and risk management 20081201

• Targeting liver myofibroblasts: a novel approach in anti-fibrogenic therapy.

  Hepatology international 20081201

• Current and future anti-fibrotic therapies for chronic liver disease.

  Clinics in liver disease 20081101

• Potent antioxidant role of pirfenidone in experimental cirrhosis.

  European journal of pharmacology 20081024

• Fibrogenic polymorphisms (TGF-beta, PAI-1, AT) in Mexican patients with established liver fibrosis. Potential correlation with pirfenidone treatment.

  Journal of investigative medicine : the official publication of the American Federation for Clinical Research 20081001

• Do drugs that block transforming growth factor beta reduce posthaemorrhagic ventricular dilatation in a neonatal rat model?

  Acta paediatrica (Oslo, Norway : 1992) 20080901

• Antifibrotic action of pirfenidone and prednisolone: different effects on pulmonary cytokines and growth factors in bleomycin-induced murine pulmonary fibrosis.

  European journal of pharmacology 20080820

• Superoxide scavenging activity of pirfenidone-iron complex.

  Biochemical and biophysical research communications 20080718

• Pharmacokinetics and clinical effects of pirfenidone administered intravenously in horses.

  American journal of veterinary research 20080701

• Acute exacerbation of idiopathic pulmonary fibrosis: a systematic review.

  European journal of internal medicine 20080601

• Effects of three anti-TNF-alpha drugs: etanercept, infliximab and pirfenidone on release of TNF-alpha in medium and TNF-alpha associated with the cell in vitro.

  International immunopharmacology 20080501

• Protective effects of pirfenidone on D-galactosamine and lipopolysaccharide-induced acute hepatotoxicity in rats.

  Inflammation research : official journal of the European Histamine Research Society ... [et al.] 20080401

• Pharmacokinetics and metabolism of intravenous pirfenidone in sheep.

  Biopharmaceutics & drug disposition 20080301

• Pirfenidone inhibits the expression of HSP47 in TGF-beta1-stimulated human lung fibroblasts.

  Life sciences 20080116

• Pirfenidone prevents capsular contracture after mammary implantation.

  Aesthetic plastic surgery 20080101

• The role of aldosterone blockade in murine lupus nephritis.

  Arthritis research & therapy 20080101

• Idiopathic pulmonary fibrosis.

  Orphanet journal of rare diseases 20080101

• Aggressive juvenile fibromatosis of the paranasal sinuses: case report and brief review.

  Journal of hematology & oncology 20080101

• p63 - Key molecule in the early phase of epithelial abnormality in idiopathic pulmonary fibrosis.

  Experimental and molecular pathology 20071201

• Single- and multiple-dose pharmacokinetics of pirfenidone, an antifibrotic agent, in healthy Chinese volunteers.

  Journal of clinical pharmacology 20071001

• Do we have a pill for renal fibrosis?

  Clinical journal of the American Society of Nephrology : CJASN 20070901

• Pirfenidone slows renal function decline in patients with focal segmental glomerulosclerosis.

  Clinical journal of the American Society of Nephrology : CJASN 20070901

• Pirfenidone: a novel potential therapeutic agent in the management of chronic allograft rejection.

  Transplantation proceedings 20070901

• Novel oral agents for multiple sclerosis.

  Current neurology and neuroscience reports 20070501

• Phase I trial of pirfenidone in children with neurofibromatosis 1 and plexiform neurofibromas.

  Pediatric neurology 20070501

• Idiopathic pulmonary fibrosis.

  The Journal of the Association of Physicians of India 20070501

• Gateways to clinical trials.

  Methods and findings in experimental and clinical pharmacology 20070401

• Pirfenidone inhibits TGF-beta expression in malignant glioma cells.

  Biochemical and biophysical research communications 20070309

• A comparison of factors associated with collagen metabolism in different skeletal muscles from dystrophic (mdx) mice: impact of pirfenidone.

  Muscle & nerve 20070201

• Influence of pirfenidone on airway hyperresponsiveness and inflammation in a Brown-Norway rat model of asthma.

  Pulmonary pharmacology & therapeutics 20070101

• The role of PDGF in radiation oncology.

  Radiation oncology (London, England) 20070101

• Accelerated variant of idiopathic pulmonary fibrosis: clinical behavior and gene expression pattern.

  PloS one 20070101

• Oral pirfenidone in patients with chronic fibrosis resulting from radiotherapy: a pilot study.

  Radiation oncology (London, England) 20070101

• Evolving concepts of liver fibrogenesis provide new diagnostic and therapeutic options.

  Comparative hepatology 20070101

• Platelet-derived growth factor as a therapeutic target for systemic autoimmune diseases.

  Drug target insights 20070101

• Simple determination of pirfenidone in rat plasma via high-performance liquid chromatography.

  Biomedical chromatography : BMC 20061201

• Phase II trial of pirfenidone in adults with neurofibromatosis type 1.

  Neurology 20061128

• A pilot study in patients with established advanced liver fibrosis using pirfenidone.

  Gut 20061101

• Pirfenidone prevents the development of a vulnerable substrate for atrial fibrillation in a canine model of heart failure.

  Circulation 20061017

• Pirfenidone modulates airway responsiveness, inflammation, and remodeling after repeated challenge.

  American journal of respiratory cell and molecular biology 20060901

• Long-term administration of pirfenidone improves cardiac function in mdx mice.

  Muscle & nerve 20060901

• Low dose pirfenidone suppresses transforming growth factor beta-1 and tissue inhibitor of metalloproteinase-1, and protects rats from lung fibrosis induced by bleomycina.

  Chinese medical sciences journal = Chung-kuo i hsueh k'o hsueh tsa chih 20060901

• Novel pirfenidone analogues: synthesis of pyridin-2-ones for the treatment of pulmonary fibrosis.

  Archiv der Pharmazie 20060801

• Pirfenidone for the treatment of idiopathic pulmonary fibrosis.

  Expert opinion on investigational drugs 20060701

• [Newly developed therapeutic drugs for idiopathic interstitial pneumonias].

  Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine 20060610

• Promising pharmacologic innovations in treating pulmonary fibrosis.

  Current opinion in pharmacology 20060601

• Current perspectives on the treatment of idiopathic pulmonary fibrosis.

  Proceedings of the American Thoracic Society 20060601

• Pirfenidone: anti-fibrotic agent with a potential therapeutic role in the management of transplantation patients.

  European journal of pharmacology 20060501

• Microsphere-based protease assays and screening application for lethal factor and factor Xa.

  Cytometry. Part A : the journal of the International Society for Analytical Cytology 20060501

• [Pulmonary fibrosis--a therapeutic dilemma?].

  Medizinische Klinik (Munich, Germany : 1983) 20060415

• Pirfenidone and chronic progressive obliterative airway disease.

  The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation 20060401

• Therapeutic management of idiopathic pulmonary fibrosis: an evidence-based approach.

  Clinics in chest medicine 20060301

• EM703 improves bleomycin-induced pulmonary fibrosis in mice by the inhibition of TGF-beta signaling in lung fibroblasts.

  Respiratory research 20060101

• Pulmonary fibrosis in hermansky-pudlak syndrome. a case report and review.

  Respiration; international review of thoracic diseases 20060101

• Sequential testing for efficacy in clinical trials with non-transient effects.

  Statistics in medicine 20051115

• Poor choice of primary outcome in a clinical trial of pirfenidone in patients with IPF.

  American journal of respiratory and critical care medicine 20051101

• The questionable efficacy of pirfenidone in IPF.

  American journal of respiratory and critical care medicine 20051101

• Pirfenidone for the treatment of idiopathic pulmonary fibrosis: therapeutic potential prompts further investigation.

  Expert opinion on investigational drugs 20051101

• Pirfenidone inhibits obliterative airway disease in mouse tracheal allografts.

  The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation 20051001

• Gateways to clinical trials.

  Methods and findings in experimental and clinical pharmacology 20051001

• Pirfenidone inhibits inflammatory responses and ameliorates allograft injury in a rat lung transplant model.

  The Journal of thoracic and cardiovascular surgery 20050901

• Pirfenidone inhibits lung allograft fibrosis through L-arginine-arginase pathway.

  American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons 20050601

• Treatment of idiopathic pulmonary fibrosis: is there anything new?

  Respirology (Carlton, Vic.) 20050601

• [Drug treatments for idiopathic pulmonary fibrosis].

  Revue de pneumologie clinique 20050601

• The experimental agent pirfenidone reduces pro-fibrotic gene expression in a model of tacrolimus-induced nephrotoxicity.

  The Journal of surgical research 20050515

• Double-blind, placebo-controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosis.

  American journal of respiratory and critical care medicine 20050501

• Is idiopathic pulmonary fibrosis now treatable?

  American journal of respiratory and critical care medicine 20050501

• [Interstitial pneumonia].

  Nihon rinsho. Japanese journal of clinical medicine 20050501

• Protection of pirfenidone against an early phase of oleic acid-induced acute lung injury in rats.

  The Journal of pharmacology and experimental therapeutics 20050401

• A double-blind, randomized, controlled study of oral pirfenidone for treatment of secondary progressive multiple sclerosis.

  Multiple sclerosis (Houndmills, Basingstoke, England) 20050401

• Effect of pirfenidone on apoptosis-regulatory genes in chronic cyclosporine nephrotoxicity.

  Transplantation 20050227

• Pirfenidone and candesartan ameliorate morphological damage in mild chronic anti-GBM nephritis in rats.

  Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20050101

• Retardation of kidney failure -- applying principles to practice.

  Annals of the Academy of Medicine, Singapore 20050101

• [Expectation of new treatments for idiopathic interstitial pneumonias].

  Nihon Ronen Igakkai zasshi. Japanese journal of geriatrics 20050101

• The novel antifibrotic agent pirfenidone attenuates the profibrotic environment generated by calcineurin inhibitors in the rat salt-depletion model.

  Transplantation proceedings 20050101

• Primary progressive multiple sclerosis : current and future treatment options.

  CNS drugs 20050101

• Expression of HSP47 in usual interstitial pneumonia and nonspecific interstitial pneumonia.

  Respiratory research 20050101

• Symptomatic and disease-modifying therapies for multiple sclerosis: recent developments: highlights of the 9th Annual Meeting of the Americas Committee for Treatment and Research in Multiple Sclerosis, October 3, 2004, Toronto, Ontario, Canada.

  Reviews in neurological diseases 20050101

• Effects of topical application of pirfenidone ointment on thermoplasty-induced acute lameness in a double-blind and acute and chronic lameness of musculoskeletal origin in an open multi-centered field trial in horses.

  Research communications in molecular pathology and pharmacology 20050101

• Transforming growth factor-beta: a clinical target for the treatment of diabetic nephropathy.

  Current diabetes reports 20041201

• Pirfenidone inhibits the induction of iNOS stimulated by interleukin-1beta at a step of NF-kappaB DNA binding in hepatocytes.

  Journal of hepatology 20041101

• The anti-fibrotic effect of pirfenidone in rat liver fibrosis is mediated by downregulation of procollagen alpha1(I), TIMP-1 and MMP-2.

  Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver 20041101

• Pharmacokinetics of orally administered pirfenidone in male and female beagles.

  Journal of veterinary pharmacology and therapeutics 20041001

• Pirfenidone protects endotoxin-induced liver injury after hepatic ischemia in rats.

  Transplantation proceedings 20040901

• Effects of pirfenidone on endotoxin-induced liver injury after partial hepatectomy in rats.

  Transplantation proceedings 20040901

• Effect of pirfenidone on induction of chemokines in rat hepatocytes.

  Transplantation proceedings 20040901

• Idiopathic pulmonary fibrosis: emerging concepts on pharmacotherapy.

  Expert opinion on pharmacotherapy 20040801

• Pirfenidone attenuates expression of HSP47 in murine bleomycin-induced pulmonary fibrosis.

  The European respiratory journal 20040701

• Potential nonhormonal therapeutics for medical treatment of leiomyomas.

  Seminars in reproductive medicine 20040501

• Gateways to clinical trials.

  Methods and findings in experimental and clinical pharmacology 20040501

• Pirfenidone inhibits obliterative airway disease in a murine heterotopic tracheal transplant model.

  Transplantation 20040315

• New perspectives in treatment of glomerulonephritis.

  Pediatric nephrology (Berlin, Germany) 20040301

• Amelioration of doxorubicin-induced cardiac and renal toxicity by pirfenidone in rats.

  Cancer chemotherapy and pharmacology 20040201

• Pirfenidone.

  IDrugs : the investigational drugs journal 20040201

• Pirfenidone prevents endotoxin-induced liver injury after partial hepatectomy in rats.

  Journal of hepatology 20040101

• Idiopathic pulmonary fibrosis: pathogenesis and therapeutic approaches.

  Drugs 20040101

• Prevention of progressive fibrosis in chronic renal diseases: antifibrotic agents.

  Journal of nephrology 20040101

• Antirheumatic effect of pirfenidone in a double blind clinical pilot trial in humans.

  Research communications in molecular pathology and pharmacology 20040101

• Gateways to clinical trials.

  Methods and findings in experimental and clinical pharmacology 20031201

• Gateways to clinical trials.

  Methods and findings in experimental and clinical pharmacology 20031101

• Differential effects of pirfenidone on acute pulmonary injury and ensuing fibrosis in the hamster model of amiodarone-induced pulmonary toxicity.

  Toxicological sciences : an official journal of the Society of Toxicology 20030901

• Desmoid tumors in familial adenomatous polyposis: a pilot project evaluating efficacy of treatment with pirfenidone.

  The American journal of gastroenterology 20030801

• Pirfenidone suppressed the development of glomerulosclerosis in the FGS/Kist mouse.

  Journal of Korean medical science 20030801

• Open-label study of pirfenidone in patients with progressive forms of multiple sclerosis.

  Multiple sclerosis (Houndmills, Basingstoke, England) 20030601

• Inhibition of experimental acute pulmonary inflammation by pirfenidone.

  Pulmonary pharmacology & therapeutics 20030101

• Modulation of articular chondrocyte activity by pirfenidone.

  Research communications in molecular pathology and pharmacology 20030101

• Pirfenidone effectively reverses experimental liver fibrosis.

  Journal of hepatology 20021201

• Open-label compassionate use one year-treatment with pirfenidone to patients with chronic pulmonary fibrosis.

  Internal medicine (Tokyo, Japan) 20021201

• Pirfenidone attenuates ischaemia-reperfusion injury in the rat small intestine.

  Clinical and experimental pharmacology & physiology 20021101

• Effect of pirfenidone on rat hepatic stellate cell proliferation and collagen production.

  Journal of hepatology 20021101

• Gateways to clinical trials.

  Methods and findings in experimental and clinical pharmacology 20021101

• [Treatment of pulmonary fibrosis].

  Presse medicale (Paris, France : 1983) 20021019

• Gateways to clinical trials.

  Methods and findings in experimental and clinical pharmacology 20021001

• From anti-inflammatory drugs through antifibrotic agents to lung transplantation: a long road of research, clinical attempts, and failures in the treatment of idiopathic pulmonary fibrosis.

  Chest 20020901

• Effect of pirfenidone against vanadate-induced kidney fibrosis in rats.

  Biochemical pharmacology 20020801

• Pirfenidone inhibits early neointimal proliferation following arterial injury.

  Transplantation proceedings 20020801

• Pharmacokinetics and metabolism of a novel antifibrotic drug pirfenidone, in mice following intravenous administration.

  Biopharmaceutics & drug disposition 20020701

• Effect of pirfenidone on the pulmonary fibrosis of Hermansky-Pudlak syndrome.

  Molecular genetics and metabolism 20020701

• Pirfenidone suppresses tumor necrosis factor-alpha, enhances interleukin-10 and protects mice from endotoxic shock.

  European journal of pharmacology 20020620

• A novel anti-fibrotic agent pirfenidone suppresses tumor necrosis factor-alpha at the translational level.

  European journal of pharmacology 20020620

• Pirfenidone blocks the in vitro and in vivo effects of staphylococcal enterotoxin B.

  Infection and immunity 20020601

• Sustained ER Ca2+ depletion suppresses protein synthesis and induces activation-enhanced cell death in mast cells.

  The Journal of biological chemistry 20020419

• Pirfenidone inhibits early myointimal proliferation but has no effect on late lesion size in rats.

  European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery 20020301

• Retinoic acid exacerbates experimental radiation nephropathy.

  Radiation research 20020201

• Attenuation of cardiac fibrosis by pirfenidone and amiloride in DOCA-salt hypertensive rats.

  British journal of pharmacology 20020201

• Pirfenidone treatment decreases transforming growth factor-beta1 and matrix proteins and ameliorates fibrosis in chronic cyclosporine nephrotoxicity.

  American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons 20020201

• Growth factors in idiopathic pulmonary fibrosis: relative roles.

  Respiratory research 20020101

• Pirfenidone in the treatment of primary sclerosing cholangitis.

  Digestive diseases and sciences 20020101

• Pirfenidone: A novel anti-fibrotic agent and progressive chronic allograft rejection.

  Pulmonary pharmacology & therapeutics 20020101

• Idiopathic pulmonary fibrosis: current and future treatment options.

  American journal of respiratory medicine : drugs, devices, and other interventions 20020101

• Antifibrotic therapy for the treatment of pulmonary fibrosis.

  The American journal of the medical sciences 20011001

• Pirfenidone for chronic progressive multiple sclerosis.

  Multiple sclerosis (Houndmills, Basingstoke, England) 20011001

• Modulation of airway remodeling-associated mediators by the antifibrotic compound, pirfenidone, and the matrix metalloproteinase inhibitor, batimastat, during acute lung injury in mice.

  European journal of pharmacology 20010824

• Pirfenidone inhibits dimethylnitrosamine-induced hepatic fibrosis in rats.

  Clinical and experimental pharmacology & physiology 20010701

• Reversal of cardiac and renal fibrosis by pirfenidone and spironolactone in streptozotocin-diabetic rats.

  British journal of pharmacology 20010701

• A phase II trial of pirfenidone (5-methyl-1-phenyl-2-[1H]-pyridone), a novel anti-fibrosing agent, in myelofibrosis with myeloid metaplasia.

  British journal of haematology 20010701

• The balance between collagen synthesis and degradation in diffuse lung disease.

  Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG 20010301

• Effects of pirfenidone on vascular smooth muscle cell proliferation and intimal hyperplasia following arterial balloon injury.

  Transplantation proceedings 20010101

• Pirfenidone reduces in vitro rat renal fibroblast activation and mitogenesis.

  Journal of nephrology 20010101